Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.

The benefit of implantable cardioverter-defibrillator (ICD) therapy depends upon appropriate evaluation of a persisting risk of sudden death and estimation of the patient's overall survival. Assessment of a stable and unchangeable arrhythmogenic substrate is often difficult. Structural abnormality and ventricular dysfunction, the two major risk parameters, may recover, and heart failure symptoms can improve so that ICD therapy may not be indicated. Risk stratification can take time while the patient continues to be at high risk of arrhythmic death, and patients may need temporary bridging by a defibrillator in cases of interrupted ICD therapy. The wearable cardioverter-defibrillator (WCD) combines a long-term electrocardiogram (ECG)-monitoring system with an external automatic defibrillator. The LIfeVest® (ZOLL, Pittsburgh, PA, USA) is composed of a garment, containing two defibrillation patch electrodes on the back, and an elastic belt with a front-defibrillation patch electrode and four non-adhesive ECG electrodes, connected to a monitoring and defibrillation unit. The WCD is a safe and effective tool to terminate ventricular tachycardia/ventricular fibrillation events, unless a conscious patient withholds shock delivery. It may be used in patients in the early phase after acute myocardial infarction with poor left ventricular function, after acute coronary revascularization procedures (percutaneous coronary intervention or coronary artery bypass grafting) and reduced left ventricular ejection fraction (≤35%), in patients with acute heart failure in non-ischaemic cardiomyopathy of uncertain aetiology and prognosis. The WCD may be helpful in subjects with syncope of assumed tachyarrhythmia origin or in patients with inherited arrhythmia syndromes. The WCD may replace ICD implantation in patients waiting for heart transplantation or who need a ventricular-assist device. This review describes the technical details and characteristics of the WCD, discusses its various potential applications, and reports the currently available experience with the wearable defibrillator.

[1]  H. Ogawa,et al.  Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. , 2001, Journal of the American College of Cardiology.

[2]  S. Szymkiewicz,et al.  Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. , 2012, Journal of cardiac failure.

[3]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[4]  Andrew Wang,et al.  SY.3.1 CLINICAL CHARACTERISTICS AND OUTCOME OF INFECTIVE ENDOCARDITIS INVOLVING IMPLANTABLE CARDIAC DEVICES , 2013 .

[5]  Aaron Lewicke,et al.  Exploring QT interval changes as a precursor to the onset of ventricular fibrillation/tachycardia. , 2009, Journal of electrocardiology.

[6]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[7]  D. K. Shakir,et al.  Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management , 2009, Journal of clinical medicine research.

[8]  C. Ayers,et al.  The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation. , 2012, American heart journal.

[9]  Michael Böhm,et al.  Predictors of Outcome in Patients With Suspected Myocarditis , 2008, Circulation.

[10]  S. Szymkiewicz,et al.  Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. , 2011, The American journal of cardiology.

[11]  P. Binkley,et al.  Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event. , 2008, American heart journal.

[12]  M. Josephson,et al.  Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[13]  R. Kerber,et al.  ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). , 2002, Circulation.

[14]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[15]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Circulation.

[16]  Sana M. Al-Khatib,et al.  Non-evidence-based ICD implantations in the United States. , 2011, JAMA.

[17]  Robert S Sheldon,et al.  Noninvasive risk assessment early after a myocardial infarction the REFINE study. , 2007, Journal of the American College of Cardiology.

[18]  G. Laufer,et al.  Survival Benefit of the Implantable Cardioverter-Defibrillator in Patients on the Waiting List for Cardiac Transplantation , 2001, Circulation.

[19]  M. Hannan,et al.  Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. , 2012, JAMA.

[20]  Li Cui-lan.  Prevention of Torsade de Pointes in Hospital Settings , 2011 .

[21]  D. Mancini,et al.  Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  Michael J Ackerman,et al.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. , 2010, Circulation.

[23]  M. Chung,et al.  Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. , 2010, Journal of the American College of Cardiology.

[24]  Ó. Cano,et al.  Defibrillator implantation early after myocardial infarction. , 2010, The New England journal of medicine.

[25]  Wojciech Zareba,et al.  Reduction in inappropriate therapy and mortality through ICD programming. , 2012, The New England journal of medicine.

[26]  C. Canter,et al.  A Fatal Device‐Device Interaction between a Wearable Automated Defibrillator and a Unipolar Ventricular Pacemaker , 2008, Pacing and clinical electrophysiology : PACE.

[27]  I. Khan,et al.  Transient left ventricular apical ballooning: a novel heart syndrome. , 2005, International journal of cardiology.

[28]  Min Zhang,et al.  Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. , 2008, European heart journal.

[29]  H. Uno,et al.  Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both , 2010, Circulation.

[30]  S. Szymkiewicz,et al.  Evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm. , 2010, Journal of electrocardiology.

[31]  Eric Fain,et al.  Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.

[32]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[33]  N. Smedira,et al.  Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. , 2010, Heart rhythm.

[34]  S. Szymkiewicz,et al.  Wearable defibrillator use in heart failure (WIF): results of a prospective registry , 2012, BMC Cardiovascular Disorders.

[35]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[36]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[37]  Terry M Therneau,et al.  Sudden death after myocardial infarction. , 2008, JAMA.

[38]  S. Szymkiewicz,et al.  Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. , 1998, The American journal of cardiology.

[39]  Daniel R. Frisch,et al.  16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. , 2011, Journal of the American College of Cardiology.

[40]  W. Winkelmayer,et al.  Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[42]  S. Szymkiewicz,et al.  Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD) , 2010, Pacing and clinical electrophysiology : PACE.

[43]  A. Khasnis,et al.  Prophylactic Defibrillator Implantation in Patients With Nonischemic Dilated Cardiomyopathy , 2004 .

[44]  H. Imaoka,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[45]  C. Herzog,et al.  Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. , 2011, Kidney international.

[46]  S. Szymkiewicz,et al.  Clinical Efficacy of a Wearable Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shocks , 2003, Pacing and clinical electrophysiology : PACE.

[47]  U. Elkayam.  Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. , 2011, Journal of the American College of Cardiology.

[48]  Maria Grazia Bongiorni,et al.  Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). , 2009, Heart rhythm.

[49]  B. Wilkoff,et al.  Transvenous Lead Extraction , 2011 .

[50]  S. Solomon,et al.  Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. , 2005, The New England journal of medicine.

[51]  M. Chung,et al.  Early Risk of Mortality After Coronary Artery Revascularization in Patients With Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator , 2013, Circulation. Arrhythmia and electrophysiology.

[52]  B. Jensen,et al.  Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. , 2012, American heart journal.

[53]  G. Russell,et al.  Characteristics of sudden death in hemodialysis patients. , 2006, Kidney international.

[54]  M. Rosenqvist,et al.  Primary prevention of defibrillator implantation after myocardial infarction: clinical practice and compliance to guidelines. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[55]  R. Foley,et al.  Long interdialytic interval and mortality among patients receiving hemodialysis. , 2011, The New England journal of medicine.

[56]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[57]  Mark Harvey,et al.  Use of a Wearable Defibrillator in Terminating Tachyarrhythmias in Patients at High Risk for Sudden Death: , 2004, Pacing and clinical electrophysiology : PACE.

[58]  J. Légaré,et al.  Implantable cardioverter-defibrillator implantation as a bridge to cardiac transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[59]  S. Solomon,et al.  Recovery of Ventricular Function after Myocardial Infarction in the Reperfusion Era: The Healing and Early Afterload Reducing Therapy Study , 2001, Annals of Internal Medicine.

[60]  Abdulrahman M El-Sayed,et al.  In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. , 2012, American heart journal.

[61]  E. Edwards.  Home Use of Automated External Defibrillators for Sudden Cardiac Arrest , 2008 .

[62]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[63]  References , 1971 .

[64]  Barry J Maron,et al.  Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[65]  R. Passman,et al.  Implantable cardioverter-defibrillator therapy after acute myocardial infarction: the results are not shocking. , 2009, Journal of the American College of Cardiology.